Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
PFOCUSNSE
SAGILITYNSE
SYNGENENSE
HORIZONINDNSE
INDGNNSE
IGILNSE
NESCONSE
SPARCNSE
LEAPINDNSE
SMARTWORKSNSE
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 99% | 2518% |
| - | - | - | 553% |
| -5% | -7% | -3% | 48% |
| 28% | 28% | 52% | 277% |
Peer Comparison
Symbol
PFOCUS
SAGILITY
SYNGENE
HORIZONIND
INDGN
IGIL
NESCO
LEAPIND
SPARC
SMARTWORKS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 337.15 | ₹27841 Cr | 240.88 | -0.53 | 10.52 | ₹219 Cr |
| 45.99 | ₹21305 Cr | 21.45 | 0.46 | 3.18 | ₹925 Cr |
| 381.85 | ₹15247 Cr | 68.99 | -0.22 | 16.72 | ₹317 Cr |
| 53.28 | ₹15216 Cr | — | -0.04 | 0.24 | -₹198 Cr |
| 597.1 | ₹14281 Cr | 35.62 | 4.83 | 22.82 | ₹401 Cr |
| 332.5 | ₹14138 Cr | 23.19 | 3.84 | 15.26 | ₹711 Cr |
| 1,074.1 | ₹7533 Cr | 18.08 | 14.19 | 66.2 | ₹413 Cr |
| 148.62 | ₹6540 Cr | 104.9 | 2.05 | 6.05 | ₹62 Cr |
| 205.65 | ₹6422 Cr | 4.05 | -0.64 | 49.12 | ₹1553 Cr |
| 539.2 | ₹6207 Cr | 222.71 | 1.15 | 81.21 | ₹11 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹40 Cr | ₹1853 Cr | ₹8 Cr | ₹8 Cr | ₹10 Cr | ₹27 Cr | ₹15 Cr | ₹13 Cr | ₹17 Cr | ₹17 Cr | ₹14 Cr | ₹21 Cr | ₹24 Cr | ₹48 Cr |
| ₹24 Cr | ₹2 Cr | ₹0 | ₹1 L | ₹9 Cr | ₹0 | ₹19 L | ₹4 L | ₹2 Cr | ₹4 Cr | ₹6 Cr | ₹8 Cr | ₹10 Cr | ₹11 Cr |
| ₹64 Cr | ₹1855 Cr | ₹8 Cr | ₹8 Cr | ₹19 Cr | ₹27 Cr | ₹15 Cr | ₹13 Cr | ₹18 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr | ₹34 Cr | ₹58 Cr |
| ₹76 Cr | ₹82 Cr | ₹68 Cr | ₹76 Cr | ₹64 Cr | ₹83 Cr | ₹92 Cr | ₹119 Cr | ₹113 Cr | ₹125 Cr | ₹120 Cr | ₹116 Cr | ₹129 Cr | ₹140 Cr |
| -₹10 Cr | ₹1775 Cr | -₹57 Cr | -₹66 Cr | -₹43 Cr | -₹53 Cr | -₹74 Cr | -₹103 Cr | -₹92 Cr | -₹101 Cr | -₹96 Cr | -₹83 Cr | -₹92 Cr | -₹79 Cr |
| ₹8 Cr | ₹12 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹1 Cr | ₹56 L | ₹91 L | ₹26 L | ₹26 L | ₹26 L | ₹21 L |
| -₹21 Cr | ₹1761 Cr | -₹80 Cr | -₹76 Cr | -₹52 Cr | -₹61 Cr | -₹79 Cr | -₹107 Cr | -₹96 Cr | -₹105 Cr | -₹100 Cr | -₹86 Cr | -₹95 Cr | -₹82 Cr |
| -₹21 Cr | ₹1761 Cr | -₹80 Cr | -₹76 Cr | -₹52 Cr | -₹60 Cr | -₹80 Cr | -₹107 Cr | -₹96 Cr | -₹106 Cr | -₹100 Cr | -₹86 Cr | -₹95 Cr | -₹82 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹32 Cr | ₹32 Cr | ₹32 Cr | ₹32 Cr |
| ₹1306 Cr | -₹249 Cr | ₹93 Cr | ₹480 Cr |
| ₹1306 Cr | -₹249 Cr | ₹93 Cr | ₹480 Cr |
| ₹1339 Cr | -₹217 Cr | ₹126 Cr | ₹513 Cr |
| ₹0 | ₹100 Cr | ₹0 | ₹0 |
| -₹2 Cr | -₹2 Cr | -₹1 Cr | ₹0 |
| ₹66 Cr | ₹71 Cr | ₹118 Cr | ₹130 Cr |
| ₹12 Cr | ₹8 Cr | ₹6 Cr | ₹8 Cr |
| ₹76 Cr | ₹176 Cr | ₹123 Cr | ₹138 Cr |
| — | — | — | — |
| ₹97 Cr | ₹114 Cr | ₹142 Cr | ₹148 Cr |
| ₹88 Cr | ₹94 Cr | ₹62 Cr | ₹24 Cr |
| ₹556 Cr | ₹158 Cr | ₹47 Cr | ₹5 L |
| ₹13 Cr | ₹8 Cr | ₹14 Cr | ₹6 Cr |
| ₹754 Cr | ₹374 Cr | ₹265 Cr | ₹179 Cr |
| ₹2169 Cr | ₹333 Cr | ₹514 Cr | ₹830 Cr |
| ₹85 Cr | ₹85 Cr | ₹84 Cr | ₹84 Cr |
| ₹556 Cr | ₹258 Cr | ₹47 Cr | ₹5 L |
| — | — | — | — |
| ₹144 Cr | ₹158 Cr | ₹157 Cr | ₹146 Cr |
| ₹59 Cr | ₹59 Cr | ₹50 Cr | ₹40 Cr |
| ₹85 Cr | ₹99 Cr | ₹108 Cr | ₹106 Cr |
| ₹50 L | ₹56 L | ₹1 Cr | ₹2 Cr |
| ₹121 Cr | ₹128 Cr | ₹68 Cr | ₹65 Cr |
| ₹29 Cr | ₹26 Cr | ₹25 Cr | ₹178 Cr |
| ₹306 Cr | ₹307 Cr | ₹244 Cr | ₹375 Cr |
| — | — | — | — |
| ₹0 | ₹0 | ₹2 Cr | ₹291 Cr |
| ₹8 Cr | ₹16 Cr | ₹16 Cr | ₹33 Cr |
| ₹1 Cr | ₹2 Cr | ₹155 Cr | ₹112 Cr |
| ₹1843 Cr | ₹4 Cr | ₹42 Cr | ₹4 Cr |
| ₹10 Cr | ₹4 Cr | ₹54 Cr | ₹16 Cr |
| ₹1862 Cr | ₹26 Cr | ₹269 Cr | ₹455 Cr |
| ₹1108 Cr | -₹348 Cr | ₹4 Cr | ₹276 Cr |
| ₹2169 Cr | ₹333 Cr | ₹514 Cr | ₹830 Cr |
| ₹41 | -₹7 | ₹4 | ₹16 |
| ₹41 | -₹7 | ₹4 | ₹16 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹1553 Cr | -₹343 Cr | -₹387 Cr | -₹223 Cr |
| ₹41 Cr | ₹21 Cr | -₹11 Cr | ₹7 Cr |
| -₹1865 Cr | -₹47 Cr | -₹27 Cr | ₹141 Cr |
| -₹270 Cr | -₹369 Cr | -₹425 Cr | -₹74 Cr |
| -₹239 Cr | -₹360 Cr | -₹429 Cr | -₹69 Cr |
| -₹23 Cr | ₹158 Cr | ₹392 Cr | -₹548 Cr |
| ₹261 Cr | ₹199 Cr | ₹42 Cr | ₹617 Cr |
| -₹89 L | -₹3 Cr | ₹5 Cr | -₹64 L |
| ₹2 Cr | ₹5 Cr | ₹58 L | ₹1 Cr |
| ₹8 L | ₹1 L | ₹20,000 | ₹0 |
| ₹1 Cr | ₹2 Cr | ₹5 Cr | ₹58 L |
Fundamental Ratios
Consolidated
Standalone
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 5 out of 9 oscillators
RSI
54.02Neutral
STOCH %K
82.32Sell
MACD Level(12,26)
-1.52Sell
Ultimate Oscillator
50.64Buy
Aroon Oscillator
-88.00Sell
BOP
-0.20Sell
CCI
83.24Neutral
Williams %R
-17.68Sell
Momentum
1.44Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 8
Bearish signals: 1 out of 9 moving averages
EMA 9
198.74Buy
SMA 9
195.60Buy
EMA 21
198.97Buy
SMA 21
198.19Buy
EMA 50
203.26Buy
SMA 50
204.92Sell
EMA 200
183.18Buy
SMA 200
171.53Buy
WMA 20
197.77Buy
Pivot
Pivot
Classic
Resistance 5
250.33
Resistance 4
238.70
Resistance 3
227.07
Resistance 2
215.44
Resistance 1
210.54
Pivot
203.81
Support 1
198.91
Support 2
192.18
Support 3
180.55
Support 4
168.92
Support 5
157.29
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
| 3.90% | 2.04% | 2.04% | 1.76% | 1.48% | 1.45% |
| 0.00% | 0.02% | 0.02% | 0.02% | 0.02% | 0.11% |
| 0.08% | 0.85% | 0.76% | 1.01% | 0.94% | 1.01% |
| 30.35% | 31.42% | 31.51% | 31.54% | 31.89% | 31.76% |
Bulk & block deals
Name
Hrti Private Limited
Hrti Private Limited
Hrti Private Limited
Junomoneta Finsol Private Limited
Nk Securities Research Private Limited
Microcurves Trading Private Limited
Qe Securities Llp
Junomoneta Finsol Private Limited
Hrti Private Limited
Nk Securities Research Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 26 May 2026 | Purchase | 47.78 Cr | ₹240.53 | 19.86 L | Bulk | 0.612128 | NSE |
| 26 May 2026 | Sell | 45.67 Cr | ₹240.86 | 18.96 L | Bulk | 0.584224 | NSE |
| 25 May 2026 | Purchase | 57.45 Cr | ₹226.90 | 25.32 L | Bulk | 0.780262 | NSE |
| 25 May 2026 | Purchase | 55.07 Cr | ₹227.49 | 24.21 L | Bulk | 0.745965 | NSE |
| 25 May 2026 | Purchase | 50.43 Cr | ₹227.43 | 22.17 L | Bulk | 0.683243 | NSE |
| 25 May 2026 | Purchase | 48.60 Cr | ₹228.31 | 21.29 L | Bulk | 0.656001 | NSE |
| 25 May 2026 | Purchase | 41.09 Cr | ₹227.12 | 18.09 L | Bulk | 0.557461 | NSE |
| 25 May 2026 | Sell | 54.54 Cr | ₹227.61 | 23.96 L | Bulk | 0.738402 | NSE |
| 25 May 2026 | Sell | 53.51 Cr | ₹226.35 | 23.64 L | Bulk | 0.72845 | NSE |
| 25 May 2026 | Sell | 50.45 Cr | ₹227.54 | 22.17 L | Bulk | 0.683243 | NSE |
Insider trading & SAST
Client name
Shanghvi Finance Pvt Ltd & Pacs
Shanghvi Finance Private Limited
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Jayant Shantilal Sanghvi
Sudhir Vrundavandas Valia
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 Jun 2026 | Promoter | Acquisition | — | 65.67 | 0 | — | 3.85 Cr | 19 May 2026 | Pref. Allotment | 25,16,25,095 | SAST | 29(2) | — |
| 21 May 2026 | Promoter Group | Acquisition | 11.866699 | 100 | 150 Cr | ₹38.95 | 3.85 Cr | 19 May 2026 | Preferential Offer | 3,85,10,000 | Insider Trading | — | Warrants |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 4.87 L | 10 Mar 2015 | Creation | 11,62,066 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 1.45 L | 20 Jan 2016 | Creation | 11,62,066 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 3.55 L | 19 Jan 2016 | Creation | 10,16,751 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 5 L | 14 Jan 2016 | Release | 6,62,066 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1.45 L | 20 Jan 2016 | Creation | 11,62,066 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 3.55 L | 19 Jan 2016 | Creation | 10,16,751 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 5 L | 14 Jan 2016 | Release | 6,62,066 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 18 L | 30 May 2017 | Creation | 18,00,000 | SAST | Reg31 | — |
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. The
Corporate Actions
Date
Type
Details
Company details
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Sun Pharma Advanced Research Company Share Price
203.98-1.67 (-0.81%)
+46.34% past 1 Year
News
Sparc narrows quarterly loss as revenue rises sharply
Equity
SPARC
SPARC elevates Anil Raghavan to Managing Director and CEO from August 11
Equity
SPARC
Sparc partner Ocuvex received FDA complete response letter for PDP-716 NDA
Equity
SPARC
Sparc posts sharp Q4 turnaround with large profit despite revenue decline
Equity
SPARC
US FDA Approves PRV for Sun Pharma's Seizaby to Treat Neonatal Seizures via SPARC.
Equity
SPARC
Sun Pharma Advanced Research Sells Priority Review Voucher for US $19.50 Crores.
Equity
SPARC
SPARC Reports Q3FY26 Net Loss of Rs 80.60 Crores, Slightly Wider YoY; Revenue Falls to Rs 8.50 Crores.
Equity
SPARC
SPARC Secures US FDA Rare Pediatric Disease Priority Review Voucher for Sezaby Approval.
Equity
SPARC
SPARC Plans Convertible Warrants Issue Up to Rs 600 Crores at Rs 155.80 Each.
Equity
SPARC
SPARC Resubmits Complete Response Letter for PDP-716 NDA to OCuVEX
Equity
SPARC
SPARC merges Mumbai and Baroda R&D labs, consolidating operations into two Baroda sites.
Equity
SPARC
SPARC Q2 FY2026: Net Loss Narrows YoY; Revenue Drops Amid Cost Management Gains
Equity
SPARC
Sparc: Q1 Sl Net Loss 51.90 Crores Rupees Vs Loss 95.90 Crores (Yoy) || Q1 Revenue 9.60 Crores Rupees Vs 16.80 Crores (Yoy)
Equity
SPARC
Sparc: Shares Decrease 19% Following The Failure Of Its Psoriasis Drug In Phase 2 Trials. ???
Equity
SPARC
Sun Pharma Advanced Research: Board Meeting On May 19 To Consider Fund Raising Proposal
Equity
SPARC
Sun Pharma Advanced Research: Sparc Announces Submission Of Ind Application For Sbo-154 To Usfda || Sbo-154 Set To Enter Global Phase 1 Clinical Trial For Treatment Of Advanced Solid Tumors
Equity
SPARC
Sparc: Q3 Cons Net Loss 79.50 Crores Rupees Vs Loss 99.60 Crores (Yoy) || Q3 Revenue 14.90 Crores Rupees Vs 13.80 Crores (Yoy)
Equity
SPARC
Sun Pharma: Guidance Revision Represents A Cumulative Upside Of ~€45-5.00 Crores From Royalties Over The Next Five Years
Equity
SPARC
Sun Pharma Advanced Research: Co Updates Regarding Asset Developed In Three-Year Partnership Between Co And Ucsf || Co To Receive 55% Equity In Tiller Therapeutics
Equity
SPARC
Sun Pharma Advanced Research: Co Announces Signing Of Binding Loi With Ucsf And Tiller Therapeutics For Pre-Clinical Oncology Asset And Associated Intellectual Property
Equity
SPARC